AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
8.3.2023 15:30:00 EET | Business Wire | Press release
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study launched by AriBio in Dec. 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005122/en/
AriBio completed a Phase 2 study in 2021 in mild to moderate Alzheimer’s disease patients with their lead compound AR1001, a PDE5 inhibitor with preclinical efficacy shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity, and stimulate autophagy activity to remove toxic proteins. The Phase 3 study in patients with early Alzheimer’s disease, AR1001-ADP3-US01, has been launched in the United States and plans to expand to other countries in 2023.
Fujirebio, a trusted partner for high-quality IVD testing solutions and a pioneer in neurodegenerative disease diagnostics is committed to the advancement of biomarkers to improve diagnosis of Alzheimer’s disease. Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease testing and the first to receive FDA authorization in 2022 for its Lumipulse® G β-Amyloid Ratio (1-42/ 1-40) test. Fujirebio continues to make advances in the field to provide fully automated blood-based tests for Alzheimer’s disease and other neurological disorders.
“AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration. Fujirebio is an ideal partner for us and reflects our commitment to advancements in this space. We look forward to working closely with Fujirebio to improve the detection of Alzheimer’s disease and other neurodegenerative diseases with their pioneering assays,” commented James Rock, President of AriBio Co., Ltd US Office.
“Fujirebio continues to lead the industry in the development of high quality, functional tests to improve clinicians’ ability to detect and diagnose a variety of neurodegenerative conditions. We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools,” stated Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
About Fujirebio
Fujirebio Diagnostics, Inc., a wholly owned subsidiary of H.U. Group Holdings, Inc. and Fujirebio Holdings, Inc., is a premier diagnostics company and the industry leader in cancer biomarker tests. Fujirebio Diagnostics specializes in the contract development and manufacturing for the diagnostics industry leaders and market development of novel in-vitro diagnostic products for the management of human disease states. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at www.fujirebio.com. H.U. Group Holdings, Inc. (formerly known as Miraca Holdings Inc.) is a listed company on the Tokyo Stock Exchange – TYO: 4544.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005122/en/
Contact information
James Rock – AriBio
jimrock@aribiousa.com
Chris Dague – Fujirebio
chris.dague@fujirebio-us.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TREASoURcE Final Conference: 14 April 2026, Brussels – Circular Systemic Solutions: From Demos to Deployment31.3.2026 10:32:00 EEST | Press release
The EU-funded TREASoURcE project will present its key results and policy messages at the Final Conference on 14 April 2026 in Brussels, bringing together policymakers, industry representatives, researchers, cities and civil society actors from across Europe. The full-day conference focuses on how circular economy solutions can move from pilot projects to broader deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331360899/en/ Join us in Brussels for the TREASoURcE Final Conference on circular solutions. Over four years, TREASoURcE has developed and tested scalable circular solutions across three value chains: plastics, batteries, and biobased side and waste streams. From demonstrations to deployment: addressing Europe’s scaling challenge The final conference responds to one of the key challenges facing Europe’s circular transition: how to move beyond successful local demonstrations towards wider market uptake and
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 10:00:00 EEST | Press release
Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we are solving,” said Pasquale Romano, CEO of Tempo. “Tempo represents our ability to deliver the extreme temperatures industry requires while
STV Group and Post-Quantum Successfully Trial World’s First Quantum-Resilient Drones31.3.2026 10:00:00 EEST | Press release
STV Group a.s., a European defence technology integrator with platforms deployed in Ukraine and allied theatres, and Post-Quantum, the UK cybersecurity company, today announced successful testing of the world’s first quantum-safe drones for active deployment across allied theatres. As allied nations adapt to warfighting defined by autonomous systems and drones, the ability to futureproof secure communications between drones and their operators is of paramount importance. Drone swarms procured today may be stored and deployed in future operations years later. This dynamic requires drones manufactured today incorporate encryption that’s resistant to attack by both classical and quantum computers. The collaboration combines STV’s combat-tested unmanned systems and command-and-control infrastructure with Post-Quantum’s patented post-quantum cryptography and secure radio technologies. The two companies have now successfully trialled the new approach at STV’s weapons testing facility in the
Schneider Electric Joins Thread Group Board of Directors31.3.2026 10:00:00 EEST | Press release
The Thread Group, an industry alliance addressing IoT convergence, security, power, and architecture challenges, today announced that Schneider Electric has joined its Board of Directors. A member of the Thread Group since 2015, Schneider Electric will take a more active role in shaping the future of the Thread wireless networking protocol moving forward. This addition comes at a pivotal time for the organization, with Thread recently surpassing 1000 consumer products, and as we continue to see expansion into commercial markets. Thread 1.4 delivers significant benefits for commercial and industrial applications, including seamless communication, enhanced reliability, and performance in expansive IoT deployments. "The entire Thread Group will benefit from Schneider Electric’s deeper engagement in our efforts," said Vividh Siddha, President of Thread Group. "A dedicated member for more than a decade, their expertise in energy management and building automation is invaluable, especially a
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management31.3.2026 10:00:00 EEST | Press release
Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares' platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on a powerful rules engine that enables intuitive compensation plan design, giving organizations the flexibility to model incentive structures in a fully self-service environment, unlocking new possibilities for incentive management at scale. Supporting more than 40 organizations, including Nespresso, TheFork, and Rakuten, Amalia provides real-time visibility into performance and incentive data, enabling companies to operate complex compensation programs with greater control and efficiency. “From day one, our focus has been to bring clarity to performance-based comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom